**Guideline Page and Request**

In response to the FDA approval of luspatercept-aamt for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell transfusions, request including luspatercept-aamt for symptomatic lower-risk MDS patients with ring sideroblastic anemia not responding to erythropoietin-stimulating agents.

Submission from Bristol-Myers Squibb Company (01/09/20). Request including luspatercept-aamt within the algorithm for the treatment of symptomatic anemia in patients with MDS (with no deletion 5q +/- other cytogenetic abnormalities) with a category 2A recommendation.

---

**Panel Discussion/References**

Based on the review of the data in the noted reference, the panel consensus was to include luspatercept-aamt as an option for treatment of symptomatic anemia in patients with ring sideroblastic (ring sideroblasts ≥15% or ≥5% with an *SF3B1* mutation) low-/intermediate-risk MDS with a footnote. This is a category 2A recommendation.

The footnote states: Encouraging data are emerging demonstrating effectiveness of luspatercept-aamt for treating the anemia of ring sideroblastic lower-risk MDS patients.


---

**Institution Vote**

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>ABSTAIN</th>
<th>ABSENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>0</td>
<td>2</td>
<td>4</td>
</tr>
</tbody>
</table>